We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

136 hedge funds and large institutions have $437M invested in Aerie Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

32% more capital invested

Capital invested by funds: $332M → $437M (+$105M)

26% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 38

5% more funds holding

Funds holding: 129 → 136 (+7)

25% less call options, than puts

Call options by funds: $123K | Put options by funds: $163K

Holders
136
Holders Change
+7
Holders Change %
+5.43%
% of All Funds
2.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
48
Reduced
38
Closed
21
Calls
$123K
Puts
$163K
Net Calls
-$40K
Net Calls Change
-$671K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$12.4M
2
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$7.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.63M
4
LCS
Levin Capital Strategies
New York
+$4.77M
5
RHJA
Rice Hall James & Associates
California
+$3.66M

Top Sellers

Rank Fund Capital Flow
1
William Blair Investment Management
William Blair Investment Management
Illinois
-$12.7M
2
Morgan Stanley
Morgan Stanley
New York
-$6.81M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$6.34M
4
Ameriprise
Ameriprise
Minnesota
-$4.71M
5
NHAS
Novo Holdings A/S
Denmark
-$3.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$4.02M -$153K -19,868 -4%
N
27
Nuveen
North Carolina
$3.21M +$31.4K +4,069 +1%
Charles Schwab
28
Charles Schwab
California
$3.1M +$121K +15,737 +5%
NAM
29
Nexpoint Asset Management
Texas
$2.82M – – –
DCM
30
DAFNA Capital Management
California
$2.63M – – –
Deutsche Bank
31
Deutsche Bank
Germany
$2.58M -$170K -22,085 -7%
Goldman Sachs
32
Goldman Sachs
New York
$2.49M +$358K +46,498 +20%
Walleye Capital
33
Walleye Capital
New York
$2.45M -$826K -107,213 -28%
Wellington Management Group
34
Wellington Management Group
Massachusetts
$2.44M +$465K +60,296 +29%
JAMONY
35
Jacob Asset Management of New York
California
$2.24M +$13.7K +1,780 +0.7%
Voloridge Investment Management
36
Voloridge Investment Management
Florida
$2.13M -$788K -102,208 -30%
CI Investments Inc
37
CI Investments Inc
Ontario, Canada
$2.07M +$1.75M +227,020 New
LCM
38
Laurion Capital Management
New York
$2.07M +$1.75M +227,022 New
Bank of New York Mellon
39
Bank of New York Mellon
New York
$2.02M +$168K +21,757 +11%
DA
40
DCF Advisers
Connecticut
$1.73M -$19.3K -2,500 -1%
Fidelity Investments
41
Fidelity Investments
Massachusetts
$1.68M +$1.42M +184,280 New
Stifel Financial
42
Stifel Financial
Missouri
$1.68M +$415K +53,904 +41%
EWM
43
Endurance Wealth Management
Rhode Island
$1.57M +$110K +14,334 +9%
PP
44
PDT Partners
New York
$1.46M +$929K +120,498 +298%
PPA
45
Parametric Portfolio Associates
Washington
$1.43M +$437K +56,724 +57%
Allianz Asset Management
46
Allianz Asset Management
Germany
$1.4M +$350K +45,380 +42%
Marshall Wace
47
Marshall Wace
United Kingdom
$1.17M +$991K +128,574 New
CSS
48
Cubist Systematic Strategies
Connecticut
$997K -$2.67M -346,417 -76%
Swiss National Bank
49
Swiss National Bank
Switzerland
$967K +$64K +8,300 +8%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$915K -$98.1K -12,731 -11%
1
2
3 4 5

AERI Hedge Fund Activity: Q1 2022 in Review

136 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2022, worth a combined $437M — up 32% from $332M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new AERI positions and 21 closed out — a net gain of 8 holders — while 48 added to existing stakes and 38 trimmed.

The largest buyer was UBS Group, adding an estimated $12.4M. The largest seller was William Blair Investment Management, exiting entirely with an estimated $12.7M sold.

  • 136 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2022, up from 129 in Q4 2021.
  • Funds reported $437M of Aerie Pharmaceuticals stock for Q1 2022, up 32% quarter-over-quarter.
  • 29 funds opened new Aerie Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +8 holders.
  • The largest Aerie Pharmaceuticals buyer in Q1 2022 was UBS Group, an estimated $12.4M added.
  • The largest Aerie Pharmaceuticals seller in Q1 2022 was William Blair Investment Management, an estimated $12.7M sold.

Based on aggregated 13F filings for Q1 2022.